LIFEVANTAGE CORP Long-Term Debt, Maturity, Year Five
LIFEVANTAGE CORP (LFVN) had Long-Term Debt, Maturity, Year Five of $7.53 million as of 2015-03-31, per its 10-Q filed 2015-05-06.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2015-05-06
- 2015-03-31: Long-Term Debt, Maturity, Year Five $7.53M.
- 2014-12-31: Long-Term Debt, Maturity, Year Five $12.03M.
- 2014-09-30: Long-Term Debt, Maturity, Year Five $12.03M.
- 2014-06-30: Long-Term Debt, Maturity, Year Five $4.70M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2015-03-31 | $7.53M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $12.03M 10-Q · filed 2015-02-04 |
| 2014-09-30 | $12.03M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $4.70M 10-K · filed 2014-09-10 |
| 2014-03-31 | $4.70M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $4.70M 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |